Frontotemporal dementia (FTD) encompasses a group of neurodegenerative disorders characterized by progressive deficits in behavior, language, and executive function. Unlike Alzheimer's disease, FTD typically presents with earlier onset (age 45-65) and is associated with distinct underlying pathologies including tauopathy, TDP-43 proteinopathy, and occasionally FUS inclusions [1]. The development of reliable biomarkers for FTD is crucial for accurate diagnosis, disease staging, and monitoring therapeutic responses. [1]
FTD biomarkers can be categorized based on the: [2]
The heterogeneous nature of FTD presents unique challenges for biomarker development, as different clinical syndromes are associated with distinct proteinopathies. [3]
Cerebrospinal fluid biomarkers for TDP-43 pathology are under active investigation [4]: [4]
TDP-43 fragments: [5]
Neurofilament Light Chain (NfL)))))))))))))))): [6]
Phosphorylated Tau (p-tau181, p-tau217): [8]
Synaptotagmin-1: [10]
Blood NfL has emerged as a valuable biomarker for FTD [9]: [11]
p-tau181: [12]
Genetic testing is essential for FTD diagnosis and family counseling [12]: [14]
| Gene | Protein | FTD Type | Inheritance | [15]
|------|---------|----------|-------------| [16]
| MAPT | Tau | bvFTD, PSP, CBD | Autosomal dominant | [17]
| GRN | Progranulin | bvFTD, PNFA | Autosomal dominant | [18]
| C9orf72 | Dipeptide repeats | bvFTD, ALS | Autosomal dominant |
Characteristic patterns of atrophy support FTD diagnosis [13]:
Behavioral Variant FTD:
Primary Progressive Aphasia:
FDG-PET:
Tau PET:
CSF TDP-43:
CSF Total Tau and p-tau:
Recommended biomarker panel for suspected FTD [16]:
Progression markers:
Poor prognosis markers:
| Clinical Syndrome | Key Biomarkers | Interpretation |
|---|---|---|
| bvFTD | NfL elevated, tau normal | Suggests TDP-43 FTD |
| svPPA | NfL elevated | Supports FTD |
| CBD/PSP | p-tau elevated | Suggests tauopathy |
| FTD+ALS | NfL very elevated | TDP-43 pathology |
Multi-marker approaches are under investigation [17]:
Biomarker development for FTD lags behind Alzheimer's disease but is advancing rapidly. Blood NfL has emerged as a valuable tool for diagnosis and disease monitoring, while genetic biomarkers enable precise molecular diagnosis. The heterogeneous nature of FTD requires a multimodal approach combining clinical assessment, imaging, fluid biomarkers, and genetic testing. Future developments in TDP-43-specific markers and multimodal biomarker panels promise to improve diagnostic accuracy and enable disease-modifying therapies.
The study of Frontotemporal Dementia (FTD) Biomarkers has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Rascovsky K, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134(Pt 10):2456-2477. 2011. ↩︎
Mackenzie IR, et al. TDP-43 pathology in frontotemporal dementia: classification and patterns. Acta Neuropathol. 2011;121(3):353-364. 2011. ↩︎
Rohrer JD, et al. The heritability and genetics of frontotemporal lobar degeneration. Neurology. 2009;73(18):1451-1456. 2009. ↩︎
Feneberg E, et al. TDP-43 biomarkers for amyotrophic lateral sclerosis and frontotemporal dementia. Nat Rev Neurol. 2018;14(7):421-432. 2018. ↩︎
Rohrer JD, et al. [Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, cohort study. Lancet Neurol. 2019;18(12):1103-1111](https://doi.org/10.1016/S1474-4422(19). 2019. ↩︎
Meeter LH, et al. Neurofilament light chain: a biomarker for genetic frontotemporal dementia. Ann Clin Transl Neurol. 2021;8(8):1660-1672. 2021. ↩︎
Blennow K, et al. Tau and p-tau as CSF biomarkers in ALS: a meta-analysis. J Neurol Neurosurg Psychiatry. 2020;91(10):1083-1092. 2020. ↩︎
Motyl J, et al. Mixed pathology in frontotemporal dementia: a review. J Neuropathol Exp Neurol. 2023;82(7):523-534. 2023. ↩︎
Khalil M, et al. Neurofilament light chain in blood and CSF as a biomarker in neurodegenerative disease. Nat Rev Neurol. 2022;18(11):641-657. 2022. ↩︎
Elahi FM, et al. GFAP in blood and CSF as a marker of astrogliosis in frontotemporal dementia. Neurology. 2022;99(8):e766-e777. 2022. ↩︎
Janelidze S, et al. P-tau181 in blood as a biomarker for Alzheimer's disease and frontotemporal dementia. Brain. 2023;146(3):1156-1168. 2023. ↩︎
van Mossel CA, et al. Genetic testing in frontotemporal dementia: practical and ethical considerations. Nat Rev Neurol. 2021;17(11):661-671. 2021. ↩︎
Rascovsky K, et al. MRI patterns of atrophy in frontotemporal dementia: the Lund model. Neurobiol Aging. 2011;32(4):601-609. 2011. ↩︎
Foster NL, et al. FDG-PET in frontotemporal dementia: a meta-analysis. Neurology. 2020;95(11):e1535-e1544. 2020. ↩︎
Benussi A, et al. CSF TDP-43: a promising biomarker for ALS and FTD. J Neurol Sci. 2022;440:120354. 2022. ↩︎
Boxer AL, et al. Clinical trials for frontotemporal dementia: past, present, and future. Nat Rev Neurol. 2023;19(8):465-478. 2023. ↩︎
Paterson RW, et al. A panel of biomarkers for disease progression in frontotemporal dementia. J Neurol Neurosurg Psychiatry. 2023;94(5):334-341. 2023. ↩︎
Young PN, et al. Digital biomarkers in frontotemporal dementia: a new frontier. Nat Rev Neurol. 2024;20(1):1-13. 2024. ↩︎